Replies to post #202433 on Biotech Values

[DewDiligence]

JUNO—More detail on clinical hold from Matt Herper:

http://www.forbes.com/sites/matthewherper/2016/07/07/juno-therapeutics-stops-trial-of-cancer-killing-cells-after-3-patient-deaths/#1ab3601e5d89

[n4807g]

An unfortunate development. Apparently there are a number of therapies used to prepare patients for treatment. Hopefully Juno can quickly determine what caused the adverse reaction and adjust their procedure.

[DewDiligence]

JUNO +24%/PM on resumption of interrupted phase-2 trial—without fludarabine:

http://finance.yahoo.com/news/juno-therapeutics-resume-jcar015-phase-205000686.html

Under the revised protocol, the ROCKET trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.